https://prabadinews.com/
  • October 7, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

New Clinical Data Highlight Revumenib’s Potential Beyond KMT2A-Rearranged Leukemia

New Clinical Data Highlight Revumenib’s Potential Beyond KMT2A-Rearranged Leukemia

Revumenib shows promise in treating NPM1-mutant AML, expanding its role in precision oncology and offering hope for targeted leukemia therapies.

administrator

Related Articles